Diseases [C] » Endocrine System Diseases [C19] » Parathyroid Diseases » Hypoparathyroidism
Description
A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone. MeSH
Hierarchy View
Subtype Terms (1)
22q11 Deletion Syndrome
7 drugs (6 approved, 1 experimental)
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (8)
Phase 3 Indicated Drugs (2)
Phase 2 Indicated Drugs (5)
Phase 1 Indicated Drugs (1)
Other Experimental Indicated Drugs (5)
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.